Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment

IF 0.9 Q4 GASTROENTEROLOGY & HEPATOLOGY

Gastrointestinal disorders (Basel, Switzerland) Pub Date : 2022-05-09 DOI:10.3390/gidisord4020009

G. Bodini, E. Giuliana, Irene Giberti, G. Guarona, F. Benvenuto, E. Ferretti, M. Demarzo, G. Da Rin, G. Icardi, E. Giannini

{"title":"Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment","authors":"G. Bodini, E. Giuliana, Irene Giberti, G. Guarona, F. Benvenuto, E. Ferretti, M. Demarzo, G. Da Rin, G. Icardi, E. Giannini","doi":"10.3390/gidisord4020009","DOIUrl":null,"url":null,"abstract":"Background: The antibody response to coronavirus disease 2019 (COVID-19) vaccination in patients with inflammatory bowel disease (IBD) on biological drugs is still unclear. Aim: To determine the anti-SARS-CoV-2 spike 1 (anti-S1-IgG) response rate and antibody levels following a complete COVID-19 vaccination cycle in patients with IBD on biological treatment. Methods: We assessed antibody response to COVID-19 in consecutive patients with IBD on biological drugs and without prior exposure to COVID-19. Sera were prospectively collected at baseline and at 21 days (T1), 42 days (T2), and 3 months (T3) after the first vaccine dose. Results: Among the 42 patients included in the study, the overall response rate at T3 was 97.6%, with no difference across the various biological drugs. After the first dose (T1), the response rate was higher in patients receiving anti-tumour necrosis factor (TNF) compared to patients treated with other biologics (p = 0.031). Among the responders, the anti-S1 levels were not significantly different among the various biological drugs at all study timepoints. Concomitant corticosteroids and disease activity had no impact on the response rate at all study timepoints. No unexpected side events were observed. Discussion: The antibody response to vaccination against COVID-19 in patients with IBD on biological drugs is optimal, independently of their mechanism of action. Patients treated with anti-TNF seem to have an earlier response to vaccination, while concomitant low-dose corticosteroids and disease activity does not seem to impact response. This information can be used to program vaccination and inform patients.","PeriodicalId":73131,"journal":{"name":"Gastrointestinal disorders (Basel, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2022-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastrointestinal disorders (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/gidisord4020009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The antibody response to coronavirus disease 2019 (COVID-19) vaccination in patients with inflammatory bowel disease (IBD) on biological drugs is still unclear. Aim: To determine the anti-SARS-CoV-2 spike 1 (anti-S1-IgG) response rate and antibody levels following a complete COVID-19 vaccination cycle in patients with IBD on biological treatment. Methods: We assessed antibody response to COVID-19 in consecutive patients with IBD on biological drugs and without prior exposure to COVID-19. Sera were prospectively collected at baseline and at 21 days (T1), 42 days (T2), and 3 months (T3) after the first vaccine dose. Results: Among the 42 patients included in the study, the overall response rate at T3 was 97.6%, with no difference across the various biological drugs. After the first dose (T1), the response rate was higher in patients receiving anti-tumour necrosis factor (TNF) compared to patients treated with other biologics (p = 0.031). Among the responders, the anti-S1 levels were not significantly different among the various biological drugs at all study timepoints. Concomitant corticosteroids and disease activity had no impact on the response rate at all study timepoints. No unexpected side events were observed. Discussion: The antibody response to vaccination against COVID-19 in patients with IBD on biological drugs is optimal, independently of their mechanism of action. Patients treated with anti-TNF seem to have an earlier response to vaccination, while concomitant low-dose corticosteroids and disease activity does not seem to impact response. This information can be used to program vaccination and inform patients.

查看原文本刊更多论文

炎症性肠病患者接种新冠肺炎疫苗的生物治疗反应

背景：炎症性肠病（IBD）患者对2019冠状病毒病（新冠肺炎）生物药物疫苗的抗体反应仍不清楚。目的：确定接受生物治疗的IBD患者在新冠肺炎完整疫苗接种周期后的抗SARS-CoV-2刺突1（抗S1-IgG）反应率和抗体水平。方法：我们评估了连续服用生物药物和未接触新冠肺炎的IBD患者对新冠肺炎的抗体反应。在基线和第一剂疫苗接种后21天（T1）、42天（T2）和3个月（T3）前瞻性收集血清。结果：在纳入研究的42名患者中，T3的总有效率为97.6%，不同生物药物之间没有差异。第一剂（T1）后，接受抗肿瘤坏死因子（TNF）治疗的患者的应答率高于接受其他生物制剂治疗的患者（p=0.031）。在应答者中，在所有研究时间点，各种生物药物的抗S1水平没有显著差异。在所有研究时间点，同时使用皮质类固醇和疾病活动对反应率没有影响。未观察到意外的副作用。讨论：IBD患者使用生物药物接种新冠肺炎疫苗后的抗体反应是最佳的，与它们的作用机制无关。接受抗TNF治疗的患者似乎对疫苗接种有更早的反应，而伴随的低剂量皮质类固醇和疾病活动似乎不会影响反应。这些信息可用于制定疫苗接种计划并告知患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊